RESEARCH MONOGRAPH · KDC-MN-341

5-MeO-DMT

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

58/100

5-HT1A-preferring tryptamine with intense pharmacology and a real but very young clinical story

5-MeO-DMT is the methoxylated cousin of DMT and pharmacologically pretty different despite the structural similarity. Where N,N-DMT is dominantly a 5-HT2A agonist, 5-MeO-DMT has substantially higher affinity for 5-HT1A relative to 5-HT2A, and the in vivo experience reflects that: less classical visual psychedelic phenomenology, more dissolutive/ego-attenuating effects with a much steeper dose-response curve.

Mechanism: 5-HT1A agonist with additional 5-HT2A activity, some TAAR1 agonism (probably more meaningful at endogenous-like concentrations), and sigma-1 binding similar to DMT. The receptor profile means that pharmacologically you're looking at a different biology than with N,N-DMT, even though both molecules are classified as tryptamine psychedelics. Halberstadt and Geyer's mouse behavioral work captures some of the discrimination between 5-HT1A and 5-HT2A dominant tryptamines.

The clinical research is much earlier-stage than for psilocybin or DMT but is active. GH Research (Dublin) has run phase 1 and phase 2 trials with an inhaled mebufotenin formulation in depression, with preliminary results suggesting rapid antidepressant effects after single administrations. The duration of the experience is even shorter than N,N-DMT (5-15 minutes for inhaled), which has the same clinical-practicality appeal but also a steeper safety-window concern because of the sharp dose-response.

The natural-source biology is interesting: 5-MeO-DMT is the principal active compound in the secretions of the Sonoran Desert toad (Incilius alvarius), which has driven a lot of the popular-culture framing around it. The toad-source material has obvious ethical and biological concerns at scale, which is why synthetic 5-MeO-DMT is the basis for legitimate research use.

For research it's a useful pharmacological probe for 5-HT1A-dominant tryptamine biology, distinct from N,N-DMT and from the more 5-HT2A-selective compounds. Sourcing is regulated similarly to DMT in most jurisdictions, controlled-substance handling required, synthetic supply through licensed channels.

What we like: distinct receptor profile from N,N-DMT, growing clinical evidence, biologically interesting for 5-HT1A pharmacology.

What we dont like: the dose-response is sharp enough that the safety margin is narrower than other tryptamines, the consumer-toad-source narrative has serious ecological and pharmacological issues (toad secretion is heterogeneous, contains other compounds, sourcing is harmful), and the clinical evidence is still phase 1-2 only.

Promising compound, early evidence, treat with appropriate caution.

Evidence: 50
Mechanism: 70
Reliability: 60
Safety: 50
Sourcing: 45
Value: 55
Signal: 70
Staying power: 65

Plain-language summary Intrigue 76 / 100

5-MeO-DMT is a tryptamine psychedelic chemically related to DMT but with strikingly different pharmacology: it prefers the 5-HT1A receptor over 5-HT2A, the opposite of N,N-DMT, which produces a qualitatively distinct experience generally described as an undifferentiated state rather than the visionary content of classical psychedelics. It is concentrated in the parotoid gland secretions of the Sonoran Desert toad (Bufo alvarius), the source of toad medicine ceremonies, and is found in several plants used in South American snuffs. Clinical interest in single-dose treatment for depression and substance use disorders is growing, with several small studies underway. The intensity and brevity of the experience pose unusual clinical and safety challenges. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Tryptamine / 5-HT1A-preferring psychedelic

A 5-methoxy-substituted tryptamine; a 5-HT1A-preferring psychedelic found in Bufo alvarius secretions and some plants.

Abstract

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine; CAS 1019-45-0; molecular formula C13H18N2O; molecular weight 218.30) is a tryptamine alkaloid found in the parotoid gland secretions of Bufo alvarius (Sonoran Desert toad) and in numerous plants (Anadenanthera, Virola, Phalaris). Distinct from N,N-DMT by 5-HT1A-preferring activity (5-HT1A Ki approximately 1 nM versus 5-HT2A Ki approximately 100 nM, opposite of DMT's 5-HT2A preference); the receptor profile produces qualitatively distinct subjective effects (less visual, more dissociative or unitary). Like DMT, oral activity requires MAO inhibition; smoked or vaporized forms are pharmacologically active without MAO inhibition. Phase 2 clinical trials in treatment-resistant depression are ongoing at GH Research and Beckley Psytech. Plasma half-life is approximately 12 to 19 minutes. Schedule I in the US. Used as a reference 5-HT1A-preferring psychedelic in research.

Mechanism of action

5-HT1A-preferring tryptamine psychedelic; opposite receptor preference from N,N-DMT (which prefers 5-HT2A). Produces qualitatively distinct subjective effects.

Reported research dose ranges

Smoked/vaporized 5 to 20 mg; intravenous 1 to 18 mg in research.

References

Davis AK, et al. The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use. Drug Sci Policy Law 2018.
Ermakova AO, et al. A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol 2022.
Reckweg J, et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N,N-dimethyltryptamine. Front Pharmacol 2021.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-341

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

5-MeO-DMT

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs